BSE Live
Oct 20, 12:25Prev. Close
1328.25
Open Price
1340.35
Bid Price (Qty.)
1367.00 (8)
Offer Price (Qty.)
1368.85 (1)
NSE Live
Oct 20, 12:25Prev. Close
1329.50
Open Price
1329.60
Bid Price (Qty.)
1367.00 (9)
Offer Price (Qty.)
1368.10 (4)
Key Financial Ratios of Tatva Chintan Pharma Chem (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
Per Share Ratios | ||||||
Basic EPS (Rs.) | 0.14 | 12.82 | 18.26 | 44.65 | 25.57 | |
Diluted EPS (Rs.) | 0.14 | 12.82 | 18.26 | 44.65 | 25.57 | |
Cash EPS (Rs.) | 11.96 | 23.49 | 22.57 | 47.00 | 28.92 | |
Book Value [ExclRevalReserve]/Share (Rs.) | 308.36 | 310.31 | 227.74 | 211.54 | 80.61 | |
Book Value [InclRevalReserve]/Share (Rs.) | 308.36 | 310.31 | 227.74 | 211.54 | 80.61 | |
Dividend / Share(Rs.) | 1.00 | 2.00 | 2.00 | 2.00 | 5.00 | |
Revenue from Operations/Share (Rs.) | 156.64 | 161.88 | 181.84 | 193.01 | 144.96 | |
PBDIT/Share (Rs.) | 12.57 | 31.79 | 27.23 | 52.46 | 34.99 | |
PBIT/Share (Rs.) | 0.75 | 20.85 | 22.92 | 48.77 | 31.64 | |
PBT/Share (Rs.) | 0.20 | 18.07 | 17.52 | 46.59 | 29.54 | |
Net Profit/Share (Rs.) | 0.14 | 12.55 | 18.26 | 43.31 | 25.57 | |
Profitability Ratios | ||||||
PBDIT Margin (%) | 8.02 | 19.64 | 14.97 | 27.17 | 24.13 | |
PBIT Margin (%) | 0.47 | 12.87 | 12.60 | 25.26 | 21.82 | |
PBT Margin (%) | 0.12 | 11.16 | 9.63 | 24.13 | 20.38 | |
Net Profit Margin (%) | 0.08 | 7.75 | 10.03 | 22.43 | 17.63 | |
Return on Networth / Equity (%) | 0.04 | 4.04 | 8.01 | 20.47 | 31.71 | |
Return on Capital Employed (%) | 0.24 | 6.70 | 9.95 | 22.39 | 32.97 | |
Return on Assets (%) | 0.03 | 3.60 | 5.36 | 14.71 | 16.58 | |
Total Debt/Equity (X) | 0.05 | 0.02 | 0.34 | 0.26 | 0.47 | |
Asset Turnover Ratio (%) | 0.45 | 0.48 | 0.57 | 0.89 | 1.05 | |
Liquidity Ratios | ||||||
Current Ratio (X) | 2.51 | 3.37 | 1.27 | 2.53 | 1.53 | |
Quick Ratio (X) | 1.28 | 1.71 | 0.65 | 1.58 | 0.94 | |
Inventory Turnover Ratio (X) | 2.74 | 2.56 | 1.38 | 2.22 | 2.38 | |
Dividend Payout Ratio (NP) (%) | 1,430.58 | 15.93 | 10.95 | 0.00 | 7.82 | |
Dividend Payout Ratio (CP) (%) | 16.71 | 8.51 | 8.86 | 0.00 | 6.91 | |
Earnings Retention Ratio (%) | -1,330.58 | 84.07 | 89.05 | 0.00 | 92.18 | |
Cash Earnings Retention Ratio (%) | 83.29 | 91.49 | 91.14 | 0.00 | 93.09 | |
Valuation Ratios | ||||||
Enterprise Value (Cr.) | 1,612.66 | 2,502.58 | 3,826.36 | 5,060.21 | 0.00 | |
EV/Net Operating Revenue (X) | 4.40 | 6.61 | 9.49 | 11.83 | 0.00 | |
EV/EBITDA (X) | 54.84 | 33.65 | 63.40 | 43.52 | 0.00 | |
MarketCap/Net Operating Revenue (X) | 4.33 | 6.67 | 9.17 | 11.96 | 0.00 | |
Retention Ratios (%) | -1,330.58 | 84.06 | 89.04 | 0.00 | 92.17 | |
Price/BV (X) | 2.20 | 3.48 | 7.32 | 10.91 | 0.00 | |
Price/Net Operating Revenue | 4.33 | 6.67 | 9.17 | 11.96 | 0.00 | |
Earnings Yield | 0.00 | 0.01 | 0.01 | 0.02 | 0.00 |
03.09.2025
Sell Tatva Chintan Pharma Chem; target of Rs 860: Deven Choksey
25.07.2025
Tatva Chintan Consolidated June 2025 Net Sales at Rs 116.86 crore, up 10.81% Y-o-Y
25.07.2025
Tatva Chintan Standalone June 2025 Net Sales at Rs 109.18 crore, up 16.39% Y-o-Y
06.05.2025
Buy Tatva Chintan Pharma Chem; target of Rs 1,000: ICICI Securities
25.07.2025
Tatva Chintan Consolidated June 2025 Net Sales at Rs 116.86 crore, up 10.81% Y-o-Y
25.07.2025
Tatva Chintan Standalone June 2025 Net Sales at Rs 109.18 crore, up 16.39% Y-o-Y
05.05.2025
Tatva Chintan Consolidated March 2025 Net Sales at Rs 107.86 crore, up 9.77% Y-o-Y
05.05.2025
Tatva Chintan Standalone March 2025 Net Sales at Rs 107.65 crore, up 14.6% Y-o-Y